×

Interleukin-13 binding proteins

  • US 7,915,388 B2
  • Filed: 09/07/2007
  • Issued: 03/29/2011
  • Est. Priority Date: 09/08/2006
  • Status: Active Grant
First Claim
Patent Images

1. A binding protein comprising an antigen binding domain, said binding protein capable of binding IL-13, said antigen binding domain comprising six CDRs:

  • CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein;

    CDR-H1 is selected from the group consisting of;

    X1-X2-X3-X4-X5-X6-X7 (SEQ ID NO;

         64), wherein;

    X1 is T, D, G, or S;

    X2 is S;

    X3 is D;

    X4 is M, S, Y, L, or H;

    X5 is G, W, Y, A, S, or N;

    X6 is V, I, or M; and

    X7 is D, H, S, Y, N, or G;

    residues 31-35 of SEQ ID NO;

    32;

    residues 31-35 of SEQ ID NO;

    34;

    residues 31-35 of SEQ ID NO;

    36;

    residues 31-35 of SEQ ID NO;

    38;

    residues 31-35 of SEQ ID NO;

    39;

    residues 31-35 of SEQ ID NO;

    41;

    residues 31-35 of SEQ ID NO;

    42;

    residues 31-35 of SEQ ID NO;

    44;

    residues 31-35 of SEQ ID NO;

    52;

    residues 31-35 of SEQ ID NO;

    54;

    residues 31-35 of SEQ ID NO;

    56;

    residues 31-35 of SEQ ID NO;

    58;

    residues 31-35 of SEQ ID NO;

    60; and

    residues 31-35 of SEQ ID NO;

    62;

    CDR-H2 is selected from the group consisting of;

    X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17(SEQ ID NO;

         65), wherein;

    X1 is M, E, H, R, S, G, or L;

    X2 is I or not present;

    X3 is H, Y, A, D, S, or W;

    X4 is P, S, W, or G;

    X5 is S, G, E, or D;

    X6 is D, G, S, E, or N;

    X7 is S, Y or G;

    X8 is E, N, Y, V, or R;

    X9 is T, I, or K;

    X10 is R, Y, I, D, or A;

    X11 is L, Y, D, or F;

    X12 is N, P, S, or D;

    X13 is Q, E, D, P, or S;

    X14 is K, M, S, T, A, or V;

    X15 is F, L, V, or M;

    X16 is K, R, or Q; and

    X17 is D, G, or S;

    residues 50-65 of SEQ ID NO;

    44;

    residues 52-67 of SEQ ID NO;

    46;

    residues 52-67 of SEQ ID NO;

    48;

    residues 52-67 of SEQ ID NO;

    50;

    residues 50-65 of SEQ ID NO;

    54;

    residues 50-65 of SEQ ID NO;

    56;

    residues 50-65 of SEQ ID NO;

    58;

    residues 50-65 of SEQ ID NO;

    60; and

    residues 50-65 of SEQ ID NO;

    62;

    CDR-H3 is selected from the group consisting of;

    X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14 (SEQ ID NO;

         66), wherein;

    X1 is W, T, G, Y, D, or I;

    X2 is R, A, S, G, or V;

    X3 is T, F, Y, or S;

    X4 is S, T, or Y;

    X5 is Y, F, or G;

    X6 is F, or Y;

    X7 is S, Y, I, or F;

    X8 is D, L, Y, or P;

    X9 is Y;

    X10 is G;

    X11 is Y, A, P, or E;

    X12 is F, M, S, L, or I;

    X13 is D, V, N, or K; and

    X14 is Y, or F;

    residues 99-105 of SEQ ID NO;

    32;

    residues 99-105 of SEQ ID NO;

    34;

    residues 99-109 of SEQ ID NO;

    36;

    residues 99-109 of SEQ ID NO;

    38;

    residues 99-100 of SEQ ID NO;

    42;

    residues 98-106 of SEQ ID NO;

    44;

    residues 100-112 of SEQ ID NO;

    46;

    residues 100-112 of SEQ ID NO;

    48;

    residues 100-112 of SEQ ID NO;

    50;

    residues 99-107 of SEQ ID NO;

    52;

    residues 98-107 of SEQ ID NO;

    54;

    residues 98-107 of SEQ ID NO;

    56;

    residues 98-107 of SEQ ID NO;

    58;

    residues 98-107 of SEQ ID NO;

    60; and

    residues 98-107 of SEQ ID NO;

    62;

    CDR-L1 is selected from the group consisting of;

    X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17 (SEQ ID NO;

         67), wherein;

    X1 is K, or R;

    X2 is S, or A;

    X3 is S or T;

    X4 is Q, K, or I;

    X5 is N, S, T, G, or E;

    X6 is L, T, or S;

    X7 is L, Q, or V;

    X8 is Y, N, H, D, or T;

    X9 is S, I, or T;

    X10 is S, D, N, H, or Y;

    X11 is N, or G;

    X12 is Q;

    X13 is K, F, N, E, or S;

    X14 is N, T, or S;

    X15 is Y, or F;

    X16 is L, A, or M; and

    X17 is A, D, E, H, or N;

    residues 24-39 of SEQ ID NO;

    33;

    residues 24-39 of SEQ ID NO;

    35;

    residues 24-39 of SEQ ID NO;

    37;

    residues 24-39 of SEQ ID NO;

    40;

    residues 24-39 of SEQ ID NO;

    43;

    residues 24-34 of SEQ ID NO;

    47;

    residues 24-34 of SEQ ID NO;

    49;

    residues 24-34 of SEQ ID NO;

    51;

    residues 23-36 of SEQ ID NO;

    53;

    residues 24-38 of SEQ ID NO;

    55;

    residues 24-38 of SEQ ID NO;

    57;

    residues 24-38 of SEQ ID NO;

    59;

    residues 24-38 of SEQ ID NO;

    61; and

    residues 24-38 of SEQ ID NO;

    63;

    CDR-L2 is X1-X2-X3-X4-X5-X6-X7 (SEQ ID NO;

         68), wherein;

    X1 is L, S, K, T, W, or Y;

    X2 is V, T, or A;

    X3 is S, or N;

    X4 is N, K, T, M, or R;

    X5 is R, K, or L;

    X6 is F, D, E, H, P, or A; and

    X7 is S, R, or P;

    andCDR-L3 is selected from the group consisting of;

    X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID NO;

         69), wherein;

    X1 is F, W, Q or A;

    X2 is Q or L;

    X3 is H, G, Y, W, or N;

    X4 is N, S, T, L, or Y;

    X5 is Y, T, S, E, or H;

    X6 is L, V, F, Y, N, G, P, or D;

    X7 is P, or, H;

    X8 is L, F, Y, W, or R; and

    X9 is T, or V; and

    residues 94-102 of SEQ ID NO;

    40.

View all claims
  • 7 Assignments
Timeline View
Assignment View
    ×
    ×